JP7657014B2 - Ｃｄ２０結合単一ドメイン抗体 - Google Patents

Ｃｄ２０結合単一ドメイン抗体 Download PDF

Info

Publication number
JP7657014B2
JP7657014B2 JP2018545490A JP2018545490A JP7657014B2 JP 7657014 B2 JP7657014 B2 JP 7657014B2 JP 2018545490 A JP2018545490 A JP 2018545490A JP 2018545490 A JP2018545490 A JP 2018545490A JP 7657014 B2 JP7657014 B2 JP 7657014B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
binding
vhh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507762A (ja
JP2019507762A5 (enExample
Inventor
タベルニエル，ジャン
カウウェルズ，アンジェ
デル ハイデン，ホセ ファン
Original Assignee
ブイアイビー ブイゼットダブリュー
ユニバーシテイト ヘント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブイアイビー ブイゼットダブリュー, ユニバーシテイト ヘント filed Critical ブイアイビー ブイゼットダブリュー
Publication of JP2019507762A publication Critical patent/JP2019507762A/ja
Publication of JP2019507762A5 publication Critical patent/JP2019507762A5/ja
Priority to JP2023003750A priority Critical patent/JP7706482B2/ja
Application granted granted Critical
Publication of JP7657014B2 publication Critical patent/JP7657014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018545490A 2016-03-07 2017-03-07 Ｃｄ２０結合単一ドメイン抗体 Active JP7657014B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023003750A JP7706482B2 (ja) 2016-03-07 2023-01-13 Ｃｄ２０結合単一ドメイン抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16158962.7 2016-03-07
EP16158962 2016-03-07
EP16166206.9 2016-04-20
EP16166206 2016-04-20
PCT/EP2017/055312 WO2017153402A1 (en) 2016-03-07 2017-03-07 Cd20 binding single domain antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023003750A Division JP7706482B2 (ja) 2016-03-07 2023-01-13 Ｃｄ２０結合単一ドメイン抗体

Publications (3)

Publication Number Publication Date
JP2019507762A JP2019507762A (ja) 2019-03-22
JP2019507762A5 JP2019507762A5 (enExample) 2020-04-16
JP7657014B2 true JP7657014B2 (ja) 2025-04-04

Family

ID=58231643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018545490A Active JP7657014B2 (ja) 2016-03-07 2017-03-07 Ｃｄ２０結合単一ドメイン抗体
JP2023003750A Active JP7706482B2 (ja) 2016-03-07 2023-01-13 Ｃｄ２０結合単一ドメイン抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023003750A Active JP7706482B2 (ja) 2016-03-07 2023-01-13 Ｃｄ２０結合単一ドメイン抗体

Country Status (6)

Country Link
US (2) US11248057B2 (enExample)
EP (2) EP4276114A3 (enExample)
JP (2) JP7657014B2 (enExample)
CN (1) CN109069573B (enExample)
CA (1) CA3016849A1 (enExample)
WO (1) WO2017153402A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563141A (zh) * 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2019161386A1 (en) * 2018-02-19 2019-08-22 New York University Alpha-synuclein single domain antibodies
CN111936516B (zh) 2018-03-19 2023-03-03 上海药明生物技术有限公司 新型抗egfr抗体多肽
EP3784990A4 (en) 2018-04-26 2022-06-22 The Trustees of the University of Pennsylvania COMPOSITIONS AND METHODS FOR DETECTING TUMOR-RELATED ANTIBODIES AND ANTIGENS
CN108753792B (zh) * 2018-04-28 2021-09-24 中山大学 绿色荧光蛋白纳米抗体的编码基因及其制备方法和应用
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
EP3946409A4 (en) * 2019-03-28 2023-06-21 Orionis Biosciences, Inc. CHEMICAL PROTEINS BASED ON FMS-LIKE TYROSINE KINASE-3 LIGAND (FLT3L)
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
CN110256564A (zh) * 2019-07-05 2019-09-20 石河子大学 Pd-l1抗原免疫羊驼制备pd-l1纳米抗体的方法
CN110256562B (zh) * 2019-07-05 2022-10-25 石河子大学 Pd-1纳米抗体、制备方法及其应用
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
US20230331852A1 (en) * 2019-12-05 2023-10-19 Ose Immunotherapeutics Anti-clec-1a antibodies and antigen-binding fragment thereof
TW202530257A (zh) 2019-12-09 2025-08-01 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CA3187283A1 (en) * 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
EP4182350A4 (en) * 2020-07-16 2024-12-11 Legend Biotech Ireland Limited CD20-BINDING MOLECULES AND USES THEREOF
CN116390941A (zh) * 2020-07-16 2023-07-04 南京传奇生物科技有限公司 多特异性嵌合抗原受体及其用途
CN112812189B (zh) * 2020-11-30 2022-05-17 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
AU2022269580A1 (en) * 2021-05-05 2023-10-19 Trustees Of Tufts College Vhh polypeptides that bind to interleukin 6 (il-6), compositions and methods of use thereof
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Engineered t cell receptors fused to binding domains from antibodies
KR20250008809A (ko) 2022-04-08 2025-01-15 리제너론 파마슈티칼스 인코포레이티드 다분할 수용체 및 신호전달 복합체
CA3249492A1 (en) * 2022-04-22 2023-10-26 The Regents Of The University Of Colorado, A Body Corporate COMPOSITIONS AND METHODS OF TREATMENT OF IDIOPATHIC NEPHROTIC SYNDROME
CN117024594B (zh) * 2023-09-21 2025-02-28 武汉波睿达生物科技有限公司 一种抗cd20的纳米抗体及其应用
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506258A (ja) 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE122238T1 (de) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
JP3115318B2 (ja) 1989-08-22 2000-12-04 イミュネックス・コーポレーション Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SE9201966D0 (sv) 1992-06-25 1992-06-25 Trion Forskning & Utveckling Interleukin-1beta deletion mutant
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996002561A1 (en) 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU6961796A (en) 1995-09-12 1997-04-01 Chiron Corporation Improved interleukin-6 receptor antagonist
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
US6994982B1 (en) 1999-05-05 2006-02-07 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
AU4761100A (en) 1999-05-26 2000-12-18 Kalle Saksela Methods and materials for generating sh3 domains with tailored binding properties
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
JP4863150B2 (ja) 2000-08-30 2012-01-25 ザ・ペン・ステート・リサーチ・ファンデーション インターロイキン１３のアミノ酸置換変異体
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040132094A1 (en) 2000-12-13 2004-07-08 Michael Etzerodt Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
CN104630192A (zh) 2002-10-02 2015-05-20 催化剂生物科学有限公司 制备与筛选改变特异性蛋白酶的方法
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2004063337A2 (en) 2003-01-07 2004-07-29 Dyax Corporation Kunitz domain library
TW201122103A (en) 2004-01-06 2011-07-01 Hayashibara Biochem Lab Tnf antagonists and tnf inhibitors comprising the same as the active ingredient
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
ES2565834T3 (es) 2007-06-01 2016-04-07 University Of Maryland, Baltimore Agentes de unión a receptor de Fc de región constante de inmunoglobulina
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
US20110224407A1 (en) 2008-09-09 2011-09-15 University Of Medicine And Dentistry Of New Jersey Type I Interferon Antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
WO2010066740A1 (en) 2008-12-08 2010-06-17 Complix Nv Single-chain antiparallel coiled coil proteins
CA2769619C (en) 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用
US20110262348A1 (en) 2010-03-29 2011-10-27 Vrije Universiteit Brussel Selective targeting of intratumoral cells
EP2673294B1 (en) 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
SE535863C2 (sv) 2011-07-18 2013-01-22 Atlas Copco Ind Tech Ab Hållare för motordrivet verktyg innefattande klämdelar med genomgående hål
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
EP3799880A3 (en) 2012-03-03 2021-06-23 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
CN105051067B (zh) * 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
CN110835376B (zh) 2013-07-18 2023-08-04 弗拉芒区生物技术研究所 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
SG11201600167SA (en) 2013-07-19 2016-02-26 Vib Vzw Targeted modified il-1 family members
WO2015007903A1 (en) 2013-07-19 2015-01-22 Vib Vzw Targeted modified tnf family members
AU2014292355B2 (en) 2013-07-19 2019-08-01 Centre Hospitalier Regional Universitaire De Montpellier Targeting of cytokine antagonists
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506258A (ja) 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用

Also Published As

Publication number Publication date
EP3426278A1 (en) 2019-01-16
US20220185904A1 (en) 2022-06-16
CN109069573A (zh) 2018-12-21
EP4276114A2 (en) 2023-11-15
US11248057B2 (en) 2022-02-15
EP3426278B1 (en) 2024-01-03
JP2023040247A (ja) 2023-03-22
CN109069573B (zh) 2022-04-05
JP2019507762A (ja) 2019-03-22
CA3016849A1 (en) 2017-09-14
US20190092871A1 (en) 2019-03-28
WO2017153402A1 (en) 2017-09-14
EP4276114A3 (en) 2024-02-21
JP7706482B2 (ja) 2025-07-11

Similar Documents

Publication Publication Date Title
JP7706482B2 (ja) Ｃｄ２０結合単一ドメイン抗体
US12448447B2 (en) CD8 binding agents
JP7746499B2 (ja) Ｃｌｅｃ９ａ結合物質およびその使用
US12364753B2 (en) CD8 binding agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230113

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230310

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230314

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230414

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250325

R150 Certificate of patent or registration of utility model

Ref document number: 7657014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150